Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors

The efficacy of programmed cell death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) blockade therapy has been demonstrated but is limited in patients with PD-L1(low) or immune desert tumors. This limitation can be overcome by combination therapies that include anti-vascular endothelial gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikura, Nobuyuki, Sugimoto, Masamichi, Yorozu, Keigo, Kurasawa, Mitsue, Kondoh, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717122/
https://www.ncbi.nlm.nih.gov/pubmed/34958105
http://dx.doi.org/10.3892/or.2021.8247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717122/
https://www.ncbi.nlm.nih.gov/pubmed/34958105
http://dx.doi.org/10.3892/or.2021.8247

Ejemplares similares